EHA 2026: Deep And Durable Responses With AZD0120 In Relapsed/Refractory Multiple Myeloma

At EHA 2026, Binod Dhakal, MD, MS, Assistant Professor of Medicine at the Medical College of Wisconsin, presented updated clinical and translational data from the phase 1b/2 DURGA-1 trial evaluating AZD0120 in relapsed/refractory multiple myeloma. The next-generation dual-targeted BCMA/CD19 CAR-T product demonstrated deep responses with high MRD-negativity rates, favorable safety outcomes, and sustained cellular activity, supporting its potential for outpatient administration and broader treatment access.